全乳放疗、内分泌治疗及其联合对65岁及以上早期luminal A样低危乳腺癌患者结局的影响:EUSOMA数据库分析
基于EUSOMA数据库9660例65岁及以上早期luminal A样低危乳腺癌患者,比较单纯内分泌治疗、单纯全乳放疗、联合治疗或无辅助治疗的肿瘤学结局。中位随访1.87年,多因素分析显示联合治疗显著改善同侧乳腺肿瘤复发无生存和乳腺癌特异性生存,各辅助治疗均显著降低死亡风险。
要点
- 联合治疗显著改善同侧乳腺肿瘤复发无生存(HR 0.28)和乳腺癌特异性生存(HR 0.12)。
- 单纯内分泌治疗、单纯全乳放疗及联合治疗均显著降低死亡风险。
- 该低危老年人群辅助治疗获益,但随访时间较短需谨慎解读。
核心结论
- 在65岁及以上早期luminal A样低危乳腺癌保乳术后患者中,辅助治疗对结局有积极影响。
研究设计与样本
- 回顾性队列研究,纳入2010至2022年间在EUSOMA认证乳腺中心治疗的9660例患者,来自14个欧洲国家72个乳腺中心。
- 所有肿瘤均为luminal A样、淋巴结阴性,85.8%为pT1。
- 中位随访1.87年(四分位距0.81-4.16),均值2.62年(范围0.003-13.82年)。
主要发现
- 与无辅助治疗相比,内分泌治疗联合全乳放疗显著改善同侧乳腺肿瘤复发无生存(HR 0.28,95%CI 0.10-0.79,p=0.016)和乳腺癌特异性生存(HR 0.12,95%CI 0.03-0.51,p=0.004)。
- 单纯内分泌治疗(HR 0.57,95%CI 0.35-0.90,p=0.017)、单纯全乳放疗(HR 0.51,95%CI 0.27-0.95,p=0.033)及联合治疗(HR 0.26,95%CI 0.16-0.42,p<0.001)均显著降低死亡风险。
关键数值与推荐
- 辅助治疗分布:单纯内分泌治疗806例(8.3%),单纯全乳放疗386例(4.0%),联合治疗8154例(84.4%),无辅助治疗314例(3.3%)。
临床怎么用
- 对于65岁及以上早期luminal A样低危乳腺癌保乳术后患者,辅助内分泌治疗和/或全乳放疗可改善肿瘤学结局,临床决策时可参考本真实世界证据。
局限性
- 随访时间较短(中位1.87年),可能不足以评估长期结局。
- 为回顾性数据库研究,存在选择偏倚和混杂可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To assess oncological outcomes in early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or more after conserving surgery followed by endocrine therapy (ET) and/or whole breast irradiation (WBI) or no adjuvant therapy. METHODS: Data from patients treated in EUSOMA-certified breast units between 2010 and 2022 were collected. Univariable and multivariable analyses for local, nodal, distant recurrences, breast cancer specific survival (BCSS), and overall mortality were conducted. Potential treatment-related determinants included adjuvant ET alone, WBI alone, ET+WBI or no adjuvant therapy. RESULTS: Breast cancer patients (9660) from 72 Breast Units across 14 European countries were enrolled. Tumours were pT1 in 85.8 % of cases. All tumours were luminal A-like. All patients had negative nodes. Adjuvant ET alone was prescribed for 806 (8.3 %) and WBI alone was delivered to 386 (4.0 %); ET and WBI were combined (ET+WBI) in 8154 (84.4 %) patients. No adjuvant therapy was given to 314 patients (3.3 %). The median follow-up was 1.87 years (first quartile 0.81, third quartile 4.16), and the mean was 2.62 years (range 0.003-13.82 years). Compared with no adjuvant therapy, multivariable analysis showed ET+WBI significantly improved in-breast tumour recurrence-free survival (IBTRFS) (HR 0.28, CI 95 % 0.10 -0.79; p = 0.016) and BCSS (HR 0.12; CI 95 %: 0.03 -0.51; p = 0.004). ET alone (HR 0.57; CI 95 %: 0.35 -0.90; p = 0.017), WBI alone (HR 0.51; CI 95 %: 0.27 -0.95; p = 0.033) and both treatments combined (HR 0.26; CI 95 %: 0.16 -0.42; p < 0.001) significantly lowered mortality. CONCLUSIONS: Despite a short follow-up, results from this large series of low-risk breast cancer patients who had undergone conserving surgery, showed adjuvant treatments impacted positively upon outcomes.
引用
- Aristei C, Tomatis M, Ponti A, et al. Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database. Eur J Cancer. 2026. PMID: 41690148. doi:10.1016/j.ejca.2026.116259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。